Src and CXCR4 are involved in the invasiveness of breast cancer cells with acquired resistance to lapatinib

Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: Utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment

(2015) Sílvia Cufí et al.   Oncotarget

Lapatinib induces p27Kip1-dependent G₁ arrest through both transcriptional and post-translational mechanisms

(2013) Lin Tang et al.   CELL CYCLE

PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+ breast cancer cells

(2012) Anna-Maria Jegg et al.   BREAST CANCER RESEARCH AND TREATMENT

A review on CXCR4/CXCL12 axis in oncology: No place to hide

(2012) Urszula M. Domanska et al.   EUROPEAN JOURNAL OF CANCER

Expression and functional role of CRIPTO-1 in cutaneous melanoma

(2011) A De Luca et al.   BRITISH JOURNAL OF CANCER

CXCL12 (SDF1 )-CXCR4/CXCR7 Pathway Inhibition: An Emerging Sensitizer for Anticancer Therapies?

(2011) D. G. Duda et al.   CLINICAL CANCER RESEARCH

Randomized Phase II Study of Dulanermin in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Advanced Non–Small-Cell Lung Cancer

(2011) Jean-Charles Soria et al.   JOURNAL OF CLINICAL ONCOLOGY

Quercetin-3-methyl ether inhibits lapatinib-sensitive and -resistant breast cancer cell growth by inducing G2/M arrest and apoptosis

(2011) Jixia Li et al.   MOLECULAR CARCINOGENESIS

Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways

(2011) Siyuan Zhang et al.   NATURE MEDICINE

Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition

(2011) B N Rexer et al.   ONCOGENE

HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib

(2010) Giorgio Valabrega et al.   BREAST CANCER RESEARCH AND TREATMENT

Predictive Biomarkers to Tyrosine Kinase Inhibitors for the Epidermal Growth Factor Receptor in Non-Small-Cell Lung Cancer

(2010) A. De Luca et al.   CURRENT DRUG TARGETS

Role of the EGFR ligand/receptor system in the secretion of angiogenic factors in mesenchymal stem cells

(2010) Antonella De Luca et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Loss of Phosphatase and Tensin Homolog or Phosphoinositol-3 Kinase Activation and Response to Trastuzumab or Lapatinib in Human Epidermal Growth Factor Receptor 2–Overexpressing Locally Advanced Breast Cancers

(2010) Bhuvanesh Dave et al.   JOURNAL OF CLINICAL ONCOLOGY

Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells

(2009) Amelia D’Alessio et al.   BREAST CANCER RESEARCH AND TREATMENT

Latent Bone Metastasis in Breast Cancer Tied to Src-Dependent Survival Signals

(2009) Xiang H.-F. Zhang et al.   CANCER CELL

Novel Mechanism of Lapatinib Resistance in HER2-Positive Breast Tumor Cells: Activation of AXL

(2009) L. Liu et al.   CANCER RESEARCH

SRC kinase inhibition: Targeting bone metastases and tumor growth in prostate and breast cancer

(2009) Fred Saad et al.   CANCER TREATMENT REVIEWS

Target-based therapies in breast cancer: current status and future perspectives

(2009) Nicola Normanno et al.   ENDOCRINE-RELATED CANCER

Understanding the Mechanisms Behind Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

(2009) Neil L. Spector et al.   JOURNAL OF CLINICAL ONCOLOGY

Src kinases as therapeutic targets for cancer

(2009) Lori C. Kim et al.   Nature Reviews Clinical Oncology

TRAIL Resistance of Breast Cancer Cells Is Associated with Constitutive Endocytosis of Death Receptors 4 and 5

(2008) Y. Zhang et al.   MOLECULAR CANCER RESEARCH